One notable limitation of our study is the inclusion of some patients in the non-proliferative and proliferative diabetic retinopathy groups who had a history of prior treatments, such as panretinal photocoagulation, intravitreal anti-vascular endothelial growth factor injections, or pars plana vitrectomy. This evidence concerns the gene VEGFA and proliferative diabetic retinopathy.